Table 1.

log₁₀ reduction in pVL after eight weeks

	no risk	at risk	Δ
geno2pheno-CSanger	2.4	2.3	0.1
geno2pheno-CSanger+	2.4	2.1	0.3
geno2pheno-CNGS–Sanger	2.4	1.9	0.5
geno2pheno-CNGS–Sanger+	2.4	1.7	0.7
geno2pheno-CNGS	2.4	1.0	1.4
Swenson et al.a	(2.4)	(1.4)	(1.0)

Performance comparison for the different methods regarding the median reduction of log₁₀ pVL in the different patient groups, measured in copies/ml eight weeks after the beginning of the treatment: The first number corresponds to patients that had been classified as no risk of X4 emergence and the second number is for the patients classified as at risk of X4 emergence. The third number corresponds to the difference between the medians of the ‘no risk’ and the ‘at risk’ group. The larger the Δ the better the prediction method is able to distinguish patients with treatment success from patients without treatment success.

^aIn contrast to the other approaches, parts of the test data were utilized to optimize model parameters.